FDA expands Pfizer vaccine’s booster authorization to include 16- and 17-year-olds; CDC recommends
The Food and Drug Administration today announced the widely anticipated expansion of Pfizer’s COVID-19 vaccine emergency use authorization to allow booster doses for 16- and 17-year-olds. The FDA said boosters for this age group should be administered at least six months following the completion of an initial two-dose regiment. Following FDA’s decision, the Centers for Disease Control and Prevention formally recommended boosters for this age group.
“We know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series,” said CDC Director Rochelle Walensky, M.D.
Related News Articles
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…